Addressing cell and gene treatment affordability 03-Nov-2020 By Jane Byrne A panel discussion at the Reuters Events' Cell & Gene Therapy Conference USA 2020 looked at the key challenges in the cell and gene therapy (CGT) space, namely affordability and access, and how to circumvent those.
US FDA places Mersana's ADC trial on partial hold after patient death 24-Jul-2018 By Maggie Lynch A report to the FDA of a serious adverse effect, during a clinical trial conducted by Mersana Therapeutics’, resulted in a partial hold.
